STOCK TITAN

Millennium Group and Israel Englander disclose 2.81M IMMX stake (IMMX)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report collective ownership of 2,812,230 shares of Immix Biopharma common stock, representing 5.3% of the class as shown in the filing dated 03/13/2026.

The filing states the shares are held by entities over which Millennium Management LLC and related managers have shared voting and dispositive power. A joint filing agreement among the three parties is attached and the disclosure is signed on 03/19/2026.

Positive

  • None.

Negative

  • None.

Insights

Large passive stake disclosure: 2,812,230 shares (5.3%) reported.

The filing lists 2,812,230 shares and a 5.3% ownership percentage as of 03/13/2026, attributed to entities subject to common voting and investment discretion. This is a standard beneficial-ownership disclosure required for Schedule 13G reporting.

Impact depends on trading decisions by the reporting entities; subsequent amendments or Form 13D filings would signal active intent.

Group filing signals coordinated reporting, not necessarily active control.

The Schedule 13G is accompanied by a Joint Filing Agreement dated 03/19/2026, confirming consolidated reporting by Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander. The disclosure attributes shared voting and dispositive power to those entities.

Governance implications hinge on whether the position remains passive; any change in intent would typically trigger Form 13D requirements.






45258H106

(CUSIP Number)
03/13/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Millennium Management LLC
Signature:/s/ Gil Raviv
Name/Title:Gil Raviv, Global General Counsel
Date:03/19/2026
Millennium Group Management LLC
Signature:/s/ Gil Raviv
Name/Title:Gil Raviv, Global General Counsel
Date:03/19/2026
Israel A. Englander
Signature:/s/ Israel A. Englander
Name/Title:Israel A. Englander
Date:03/19/2026
Exhibit Information

Exhibit I: Joint Filing Agreement, dated as of March 19, 2026, by and among Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.

FAQ

How many Immix Biopharma (IMMX) shares does Millennium Management report owning?

They report beneficial ownership of 2,812,230 shares, representing 5.3% of common stock. The amount and percentage are shown in the Schedule 13G filed with the dates included in the disclosure.

What date is the ownership stake reported as of in the IMMX filing?

The Schedule 13G shows the ownership information with a reporting date of 03/13/2026. Signatures and the Joint Filing Agreement in the filing are dated 03/19/2026.

Which entities are included in the joint filing for IMMX ownership?

The joint filing lists Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander. An Exhibit I Joint Filing Agreement dated 03/19/2026 is attached to the filing.

Does the filing indicate who has voting and dispositive power over the IMMX shares?

Yes; the filing reports shared voting power and shared dispositive power of 2,812,230 shares among the reporting entities, as stated on the cover-page responses referenced in Item 4.

Is the Schedule 13G filing an indication of active control or a passive stake in IMMX?

The Schedule 13G format typically indicates a passive investment; this filing reports a 5.3% stake and a joint filing agreement, but does not assert active control or intentions to influence management.
Immix Biopharma Inc

NASDAQ:IMMX

View IMMX Stock Overview

IMMX Rankings

IMMX Latest News

IMMX Latest SEC Filings

IMMX Stock Data

500.96M
40.95M
Biotechnology
Pharmaceutical Preparations
Link
United States
LOS ANGELES